National and Kapodistrian University of Athens
Καρδιαγγειακές και μεταβολικές επιδράσεις φαρμάκων κατά της παχυσαρκίας: σύγκριση της αποτελεσματικότητας της λιραγλουτίδης και του συνδυασμού ναλτρεξόνης/βουπροπιόνης ως προς τη βελτίωση μεταβολικών και καρδιαγγειακών δεικτών
Abstract
dc:descriptionObjective: The present study aims at comparing the efficacy of liraglutide vs. the combination of naltrexone/bupropion (Ν/Β) in weight loss and improving metabolic and cardiovascular risk markers. In addition, it aims to clarify the postprandial secretion of gastrointestinal hormones involved in hunger and satiety after a test meal, before and after weight loss. Patients and methods: The prospective 6-month follow-up study involved 42 people with overweight or obesity, without diabetes mellitus, who received either liraglutide 3 mg per day or N/B 32/360 mg per day, along with diet and exercise. The subjects underwent clinical and laboratory measurements at baseline, as well as at the three- and six-months’ time points. Anthropometric measurements and body composition analysis via bioelectrical impendence analysis (BIA) were conducted. Blood samples were collected at fasting state and every 30 min for three hours after the consumption of a standardized mixed meal. At the same time points, subjects completed visual analog scales assessing the subjective feelings of hunger and satiety. Results: Both drugs resulted in significant weight loss (from 115.01kg ± 17.93 to 106.39kg ± 17.75, P visit = 0.025), reduction in body fat and improvement in glycaemia. Liver fat was significantly reduced in both groups (from 8.40% to 3.50% at 3 months), while tests of autonomic cardiovascular system, cardiovascular and peripheral neuropathy showed no statistically significant changes. Hunger and satiety levels remained unchanged (P visit>0.05). Remarkable changes in peptides were mainly recorded at 3-6 months. MPGF decreased dramatically on both drugs. Ghrelin showed a greater decrease in the liraglutide group, while C-peptide decreased in both groups at 6 months. Proglucagon increased at 3 months, while at 6 months it decreased in the liraglutide group. GIP levels remained unchanged, regardless of administered treatment or weight loss.Conclusion: The aforementioned drugs cause satiety, weight loss and metabolic improvements, mainly through their effect on the hypothalamus. Despite hormonal adjustments that usually resist weight loss, drug intervention proves effective in maintaining weight loss, with the need for continued treatment for consistent results.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Konstantinidou, Sofia
- Κωνσταντινίδου, Σοφία
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58818